New approach aims to boost breast cancer treatment before surgery
NCT ID NCT07506876
Summary
This study is testing whether adding hormone therapy to standard chemotherapy and targeted drugs improves treatment results before surgery for HER2-positive breast cancer. Researchers will compare 30 patients receiving the combined approach against historical records of patients who received only chemotherapy and targeted therapy. The goal is to see if the combination leads to better tumor shrinkage and fewer cancer cells remaining at surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER - INFILTRATING DUCTAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Legacy Good Samaritan Medical Center
Portland, Oregon, 97210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Legacy Meridian Park Medical Center
Tualatin, Oregon, 97062, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Legacy Salmon Creek Medical Center
Vancouver, Washington, 98686, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.